This document is a published patent application from the USPTO, specifically application US20260083862A1, filed by the University of Iowa Research Foundation. It describes methods and compositions for treating brain diseases or delivering therapeutic agents by administering rAAV particles into the cisterna magna and/or ventricle. The vector within the particle contains a nucleic acid encoding a therapeutic protein designed to be expressed and secreted into the cerebrospinal fluid (CSF) for distribution throughout the brain.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in gene therapy and treatments for neurological disorders. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in gene therapy or CNS drug development, should monitor the progress of this and similar patent applications as they may indicate emerging therapeutic approaches or intellectual property landscapes.